Nuvectis Pharma, Inc.
NVCT
$11.04
-$1.41-11.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.90% | 25.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.82% | -2.27% | |||
| Operating Income | 17.82% | 2.27% | |||
| Income Before Tax | 17.28% | 1.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.28% | 1.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.28% | 1.98% | |||
| EBIT | 17.82% | 2.27% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 18.05% | 27.58% | |||
| Normalized Basic EPS | 18.06% | 3.99% | |||
| EPS Diluted | 18.05% | 27.58% | |||
| Normalized Diluted EPS | 18.06% | 3.99% | |||
| Average Basic Shares Outstanding | 0.94% | 2.10% | |||
| Average Diluted Shares Outstanding | 0.94% | 2.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||